Invention Application
- Patent Title: ISOQUINOLINE DERIVATIVES AS MGAT2 INHIBITORS
-
Application No.: US15104537Application Date: 2015-01-20
-
Publication No.: US20180009796A1Publication Date: 2018-01-11
- Inventor: Richard Berger , Timothy A. Blizzard , Brian T. Campbell , Helen Y. Chen , John S. Debenham , Sunita V. Dewnani , Byron Dubois , Candido Gude , Zack Zhiqiang Guo , Bart Harper , Zhiyong Hu , Songnian Lin , Ping Liu , Ming Wang , Feroze Ujjainwalla , Jiayi Xu , Libo Xu , Rui Zhang
- Applicant: Merck Sharp & Dohme Corp.
- International Application: PCT/US15/11939 WO 20150120
- Main IPC: C07D413/14
- IPC: C07D413/14 ; C07D417/14 ; C07D413/12 ; C07D471/04 ; C07D401/12
Abstract:
The compounds of Formula I act as MGAT2 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.
Public/Granted literature
- US10065945B2 Isoquinoline derivatives as MGAT2 inhibitors Public/Granted day:2018-09-04
Information query
